BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15259310)

  • 1. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
    Thorens B
    Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
    Gefel D; Barg Y; Zimlichman R
    Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of incretin hormones.
    Efendic S; Portwood N
    Horm Metab Res; 2004; 36(11-12):742-6. PubMed ID: 15655702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 and control of insulin secretion.
    Thorens B
    Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
    Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
    Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabolic role of GIP: physiology and pathology.
    Morgan LM
    Biochem Soc Trans; 1996 May; 24(2):585-91. PubMed ID: 8736808
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility.
    Miki T; Minami K; Shinozaki H; Matsumura K; Saraya A; Ikeda H; Yamada Y; Holst JJ; Seino S
    Diabetes; 2005 Apr; 54(4):1056-63. PubMed ID: 15793244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ["Glucagon-like peptide I": a therapeutic alternative for diabetes mellitus?].
    Fehmann HC; Göke B
    Dtsch Med Wochenschr; 1994 Feb; 119(8):275-9. PubMed ID: 8112212
    [No Abstract]   [Full Text] [Related]  

  • 11. Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
    Gromada J; Brock B; Schmitz O; Rorsman P
    Basic Clin Pharmacol Toxicol; 2004 Dec; 95(6):252-62. PubMed ID: 15569269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.
    Thorens B; Waeber G
    Diabetes; 1993 Sep; 42(9):1219-25. PubMed ID: 8349031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.
    Nauck MA; Baller B; Meier JJ
    Diabetes; 2004 Dec; 53 Suppl 3():S190-6. PubMed ID: 15561910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastro-intestinal hormones GIP and GLP-1.
    Kieffer TJ
    Ann Endocrinol (Paris); 2004 Feb; 65(1):13-21. PubMed ID: 15122087
    [No Abstract]   [Full Text] [Related]  

  • 16. Gut peptides and type 2 diabetes mellitus treatment.
    Ahrén B
    Curr Diab Rep; 2003 Oct; 3(5):365-72. PubMed ID: 12975025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin hormones--an update.
    Holst JJ; Orskov C
    Scand J Clin Lab Invest Suppl; 2001; 234():75-85. PubMed ID: 11713984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.
    Fehmann HC; Göke R; Göke B
    Endocr Rev; 1995 Jun; 16(3):390-410. PubMed ID: 7671853
    [No Abstract]   [Full Text] [Related]  

  • 19. Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism.
    Vahl T; D'Alessio D
    Curr Opin Clin Nutr Metab Care; 2003 Jul; 6(4):461-8. PubMed ID: 12806222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretins, insulin secretion and Type 2 diabetes mellitus.
    Vilsbøll T; Holst JJ
    Diabetologia; 2004 Mar; 47(3):357-366. PubMed ID: 14968296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.